BAUSCH Health

2016

Register for email alerts.

All Categories

Archive

Date 12/12/16

Title

Valeant Appoints William D. Humphries As EVP, Dermatology

Download PDF

Date 12/08/16

Title

Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118

Download PDF

Date 11/29/16

Title

Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor®

Download PDF

Date 11/17/16

Title

Valeant Comments On Issued Philidor Criminal Charges

Download PDF

Date 11/10/16

Title

Valeant Pharmaceuticals To Participate In Healthcare Conferences

Download PDF

Date 11/08/16

Title

Valeant Reports Third Quarter 2016 Financial Results

Download PDF

Date 11/01/16

Title

Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit

Download PDF

Date 10/31/16

Title

Valeant Pharmaceuticals Comments On Press Report

Download PDF

Date 10/17/16

Title

Valeant Announces Third Quarter Financial Results Date And Conference Call Details

Download PDF

Date 10/14/16

Title

Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions

Download PDF

Date 10/06/16

Title

Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer

Download PDF

Date 09/16/16

Title

Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel

Download PDF

Date 09/06/16

Title

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

Download PDF

Date 08/30/16

Title

Valeant Pharmaceuticals To Participate In September Healthcare Conferences

Download PDF

Date 08/22/16

Title

Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer

Download PDF

Date 08/18/16

Title

Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment

Download PDF

Date 08/10/16

Title

Valeant Pharmaceuticals Comments On SDNY Investigation

Download PDF

Date 08/09/16

Title

Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results

Download PDF

Date 08/08/16

Title

Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease

Download PDF

Date 08/08/16

Title

Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution

Download PDF

Date 08/08/16

Title

Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada

Download PDF

Date 08/08/16

Title

Valeant Pharmaceuticals Announces Changes To Executive Management Team

Download PDF

Date 07/28/16

Title

Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors

Download PDF

Date 07/22/16

Title

Valeant Pharmaceuticals Receives Complete Response Letter From The FDA

Download PDF

Date 07/19/16

Title

Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Download PDF

Date 07/19/16

Title

FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis

Download PDF

Date 07/15/16

Title

Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details

Download PDF

Date 07/14/16

Title

Valeant Pharmaceuticals Comments On Recent Stock Transactions

Download PDF

Date 07/06/16

Title

Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology

Download PDF

Date 07/01/16

Title

Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe

Download PDF

Date 06/27/16

Title

Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care

Download PDF

Date 06/17/16

Title

Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations

Download PDF

Date 06/16/16

Title

Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin

Download PDF

Date 06/15/16

Title

Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director

Download PDF

Date 06/09/16

Title

Valeant To Participate In FDA Advisory Committee Meeting On July 19

Download PDF

Date 06/07/16

Title

Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders

Download PDF

Date 06/07/16

Title

Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results

Download PDF

Date 06/03/16

Title

Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing

Download PDF

Date 06/01/16

Title

Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting

Download PDF

Date 05/31/16

Title

Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016

Download PDF

Date 05/26/16

Title

Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller

Download PDF

Date 05/23/16

Title

Bausch + Lomb Wins Walmart "Supplier of the Year" Award

Download PDF

Date 05/19/16

Title

Valeant Pharmaceuticals Receives Notice Of Default From Bondholders

Download PDF

Date 05/18/16

Title

Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference

Download PDF

Date 05/16/16

Title

Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters

Download PDF

Date 05/16/16

Title

Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel

Download PDF

Date 05/09/16

Title

Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance

Download PDF

Date 05/05/16

Title

Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs

Download PDF

Date 05/05/16

Title

Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM

Download PDF

Date 05/03/16

Title

Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals

Download PDF

Date 04/29/16

Title

Valeant Announces Nominees For Election To Board Of Directors

Download PDF

Date 04/29/16

Title

Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015

Download PDF

Date 04/25/16

Title

Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals

Download PDF

Date 04/22/16

Title

Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing

Download PDF

Date 04/13/16

Title

Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters

Download PDF

Date 04/12/16

Title

Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing

Download PDF

Date 04/11/16

Title

Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging

Download PDF

Date 04/07/16

Title

Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment

Download PDF

Date 04/05/16

Title

Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters

Download PDF

Date 04/04/16

Title

Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR

Download PDF

Date 03/30/16

Title

Valeant Pharmaceuticals Launches Credit Facility Amendment

Download PDF

Date 03/21/16

Title

Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update

Download PDF

Date 03/15/16

Title

/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./

Download PDF

Date 03/09/16

Title

Valeant And R&O Pharmacy End Litigation

Download PDF

Date 03/09/16

Title

Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board

Download PDF

Date 03/07/16

Title

Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016

Download PDF

Date 03/07/16

Title

Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016

Download PDF

Date 03/03/16

Title

Valeant Pharmaceuticals Comments On Management Change

Download PDF

Date 03/02/16

Title

Valeant Pharmaceuticals Announces Management Change

Download PDF

Date 02/28/16

Title

Valeant Pharmaceuticals Announces Management And Business Update

Download PDF

Date 02/22/16

Title

Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters

Download PDF

Date 01/25/16

Title

Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis

Download PDF

Date 01/25/16

Title

Valeant Provides Update On J. Michael Pearson

Download PDF

Date 01/06/16

Title

Valeant Names Howard B. Schiller Interim CEO

Download PDF

Date 01/04/16

Title

Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE